Program
zipalertinib
Also written as “TAS6417” and “CLN-081”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Carcinoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 33 open or running | phase 3since Jul 11, 2023 | Jul 11, 2023 | May 27, 2027phase 3 · NCT05973773 |
| Cullinan Therapeutics | 11 open or running | phase 2since Jul 23, 2019 | Jul 23, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Cullinan TherapeuticsCullinan Therapeutics · NCT04036682 · 284 enrolled · United States, Hong Kong, Italy and more
- Jul 11, 2023Otsuka's first study: phase 3 study in Lung DiseasesNew to OtsukaOtsuka · NCT05973773 · 285 enrolled · United States, Belgium, Brazil and more
- Jul 11, 2023Phase 2 study in CarcinomaOtsuka · NCT05967689 · 220 planned · United States, Australia, Canada and more
- Aug 11, 2025Phase 3 study in Lung NeoplasmsOtsuka · NCT07128199 · 360 planned · United States, Argentina, Australia and more
Ahead
- May 27, 2027Primary completion: phase 3 study in Lung DiseasesOtsuka · NCT05973773
- Aug 31, 2028Primary completion: phase 2 study in CarcinomaOtsuka · NCT05967689
- Oct 1, 2029Primary completion: phase 3 study in Lung NeoplasmsOtsuka · NCT07128199
TargetBeta
“An orally available selective inhibitor of a broad spectrum of epidermal growth factor receptor (EGFR) mutations, including EGFR exon 20 insertion mutations (EGFR Ex20ins; Ex20ins mutations), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07128199Lung Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Otsuka | Oct 1, 2029 | 360 |
| NCT05973773Lung Diseases · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Otsuka | May 27, 2027 | 285 |
| NCT05967689Carcinoma · United States, Australia, Canada and more | 2 | Recruiting | Otsuka | Aug 31, 2028 | 220 |
| NCT04036682Carcinoma, Non-Small-Cell Lung · United States, Hong Kong, Italy and more | 2 | Active, not recruiting | Cullinan Therapeutics | Oct 13, 2025 | 284 |
How it is read
Names in the registry
- “TAS6417”, 3 entries
- “CLN-081”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Lung Neoplasms, 1 study
- Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.